15315305

Source:http://linkedlifedata.com/resource/pubmed/id/15315305

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0006142, umls-concept:C0015730, umls-concept:C0144576, umls-concept:C0205179, umls-concept:C0246415, umls-concept:C0450442, umls-concept:C0453882, umls-concept:C0796419, umls-concept:C0950521, umls-concept:C1527148, umls-concept:C1707689
pubmed:issue	3
pubmed:dateCreated	2004-8-18
pubmed:abstractText	We previously designed and tested combinations made up of the CMF agents, two at a time by rotation, and of doxorubicin or epirubicin. The present study was aimed to similarly test new combinations made up of the CMF agents, two at a time by rotation, and paclitaxel or docetaxel.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0111356
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Phytogenic, http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin, http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil, http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate, http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel, http://linkedlifedata.com/resource/pubmed/chemical/Taxoids, http://linkedlifedata.com/resource/pubmed/chemical/docetaxel
pubmed:status	MEDLINE
pubmed:issn	0300-8916
pubmed:author	pubmed-author:CamisaRobertaR, pubmed-author:CocconiGiorgioG, pubmed-author:FerrozziFrancescoF, pubmed-author:PassalacquaRodolfoR, pubmed-author:SalvagniStefaniaS
pubmed:issnType	Print
pubmed:volume	90
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	280-4
pubmed:dateRevised	2008-12-12
pubmed:meshHeading	pubmed-meshheading:15315305-Adult, pubmed-meshheading:15315305-Aged, pubmed-meshheading:15315305-Antineoplastic Agents, Phytogenic, pubmed-meshheading:15315305-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:15315305-Breast Neoplasms, pubmed-meshheading:15315305-Cisplatin, pubmed-meshheading:15315305-Dose-Response Relationship, Drug, pubmed-meshheading:15315305-Drug Administration Schedule, pubmed-meshheading:15315305-Feasibility Studies, pubmed-meshheading:15315305-Female, pubmed-meshheading:15315305-Fluorouracil, pubmed-meshheading:15315305-Humans, pubmed-meshheading:15315305-Methotrexate, pubmed-meshheading:15315305-Middle Aged, pubmed-meshheading:15315305-Neoplasm Staging, pubmed-meshheading:15315305-Paclitaxel, pubmed-meshheading:15315305-Survival Analysis, pubmed-meshheading:15315305-Taxoids, pubmed-meshheading:15315305-Treatment Outcome
pubmed:articleTitle	Design and development of new combinations of the CMF agents with taxanes (paclitaxel or docetaxel) in advanced breast cancer: a feasibility study.
pubmed:affiliation	Medical Oncology Division, University Hospital, Parma, Italy. giorgio.cocconi@tin.it
pubmed:publicationType	Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't